United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

4:00pm EDT
Change (% chg)

$0.72 (+0.65%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for UTHR.OQ


United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and... (more)


Beta: 1.58
Market Cap(Mil.): $4,963.21
Shares Outstanding(Mil.): 44.55
Dividend: --
Yield (%): --


  UTHR.OQ Industry Sector
P/E (TTM): 6.16 39.80 37.05
EPS (TTM): 18.10 -- --
ROI: 58.63 -5.86 14.35
ROE: 63.76 -4.70 15.56

BRIEF-United Therapeutics qtrly non-gaap EPS $ 3.02

* United therapeutics corporation reports first quarter 2016 financial results

Apr 28 2016

BRIEF-SteadyMed says U.S. Patent and Trademark office has initiated proceeding against patent owned by United Therapeutics

* U.S. Patent and trademark office has initiated IPR proceeding against U.S. Patent No. 8,497,393 owned by United Therapeutics Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 11 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.